Voting results of the Fiscal 2025 Annual General Meeting of Pluxee Amsterdam-Schiphol, December 17, 2025 // Pluxee N.V. (“Pluxee”) held today its Annual General Meeting of Shareholders, in Amsterdam-Schipol, chaired by Didier Michaud-Daniel, Executive Chair of Pluxee’s Board of Directors. All resolutions on the agenda were approved by the shareholders. This included the adoption of the financial statements for the fiscal year which ended on August 31, 2025 (“Fiscal 2025”), and of the dividend distribution ...

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive's content includes insights across various sectors such as biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Insights - Protalix BioTherapeutics and Secarna Pharmaceuticals have entered into a collaboration and option agreement to develop antisense oligonucleotide therapies for rare renal diseases, leveraging Protalix's expertise in rare diseases and Secarna's AI-powered OligoCreator platform [1][2][3] Company Overview - Protalix BioTherapeutics focuses on innovative therapeutics for rare diseases and has developed two enzyme replacement therapies available in multiple markets, utilizing a proprietary plant cell-based expression system called ProCellEx [4][5] - Secarna Pharmaceuticals specializes in oligonucleotide therapeutics and employs its OligoCreator platform to rapidly generate high-quality antisense candidates, aiming to transform untreatable conditions into treatable ones [7] Collaboration Details - The collaboration involves Protalix selecting pharmaceutical targets for rare renal indications, while Secarna will use its OligoCreator platform to design and profile ASO candidates against these targets [2] - Protalix has the option for an exclusive, worldwide license to further develop and commercialize the therapeutic programs resulting from this collaboration [2][3] Strategic Goals - The partnership aims to advance programs from preclinical stages to clinical trials, addressing significant unmet medical needs in the rare kidney disease space [2][3] - Both companies express excitement about the collaboration, highlighting the combination of Secarna's rapid candidate generation and Protalix's experience in bringing therapies to market [3]

Regulated information Paris, December 15, 2025 DISCLOSURE FISCAL 2026/06 OF TRANSACTIONS ON TREASURY SHARES Period of: December 8 to December 12, 2025 Issuer: Pluxee N.V. Class of Securities: Ordinary shares (ISIN NL0015001W49) Aggregate presentation by day and by market. Issuer CodeTransaction dateISIN CodeDaily total volume (in number of shares)Daily weighted average price of shares acquiredPlatform213800RQNIQT48SEEO851-Dec-25NL0015001W4930 84913,6928XPAR21 ...

Regulated information Paris, December 8, 2025 DISCLOSURE FISCAL 2026/05 OF TRANSACTIONS ON TREASURY SHARES Period of: December 1 to December 5, 2025 Issuer: Pluxee N.V. Class of Securities: Ordinary shares (ISIN NL0015001W49) Aggregate presentation by day and by market. Issuer CodeTransaction dateISIN CodeDaily total volume (in number of shares)Daily weighted average price of shares acquiredPlatform213800RQNIQT48SEEO851-Dec-25NL0015001W4930,84913.6928XPAR213800RQNIQT48SEEO85<td style="width:99.8px;;text-a ...

Regulated information Paris, December 1, 2025 DISCLOSURE FISCAL 2026/04 OF TRANSACTIONS ON TREASURY SHARES Period of: November 24 to November 28, 2025 Issuer: Pluxee N.V. Class of Securities: Ordinary shares (ISIN NL0015001W49) Aggregate presentation by day and by market. Issuer CodeTransaction dateISIN CodeDaily total volume (in number of shares)Daily weighted average price of shares acquiredPlatform213800RQNIQT48SEEO8524-Nov-25NL0015001W4929 57013,9068XPAR213800RQNIQT48SEEO8524-Nov-25< ...

Core Insights - Pluxee N.V. disclosed transactions on treasury shares for the period from November 17 to November 21, 2025, indicating active management of its share buyback program [1][3]. Summary by Category Treasury Share Transactions - On November 17, 2025, Pluxee acquired a total of 49,150 shares at weighted average prices of €13.7525 on XPAR and €13.7303 on DXE [3]. - On November 18, 2025, the company purchased 50,907 shares at average prices of €13.2784 on XPAR and €13.2650 on DXE [3]. - On November 19, 2025, a total of 48,675 shares were acquired at prices of €13.4435 on XPAR and €13.4419 on DXE [3]. - On November 20, 2025, Pluxee bought 50,500 shares at average prices of €13.4074 on XPAR and €13.3687 on DXE [3]. - On November 21, 2025, the company acquired 50,138 shares at prices of €13.4876 on XPAR, €13.4690 on DXE, and €13.4400 on TQE [3]. Company Overview - Pluxee operates in 28 countries, focusing on Employee Benefits and Engagement, providing solutions in Meal & Food, Well-being, Lifestyle, Reward & Recognition, and Public Benefits [4]. - The company has over 5,600 team members and serves more than 500,000 clients, impacting over 37 million consumers and 1.7 million merchants [4]. - With over 45 years of experience, Pluxee is dedicated to positively influencing local communities and promoting employee well-being [4].

Core Insights - Nasus Pharma Ltd. has appointed Eyal Rubin as Executive Vice President and Chief Financial Officer, bringing over 20 years of financial leadership experience in the biotechnology and pharmaceutical industries [1][2][3] - Mr. Rubin will oversee financial operations, including corporate finance, financial planning, capital strategy, and investor relations, as the company advances its pipeline of intranasal therapeutics [2][3] - The leadership team believes Mr. Rubin's expertise will be crucial as the company enters a significant growth phase [3] Company Overview - Nasus Pharma is a clinical-stage pharmaceutical company focused on developing innovative intranasal products for emergency medical conditions [4] - The company's lead product candidate, NS002, is an intranasal powder formulation of Epinephrine, designed as a needle-free alternative for treating anaphylaxis [4] - The proprietary powder-based intranasal (PBI) technology aims for rapid and reliable drug delivery, leveraging the nasal cavity's vascular network for quick absorption [4]

Core Insights - Pluxee N.V. disclosed transactions on treasury shares for the period from November 10 to November 14, 2025, indicating ongoing share buyback activities [1][3]. Summary by Category Treasury Share Transactions - On November 10, 2025, Pluxee acquired a total of 43,077 shares across three transactions, with average prices ranging from €15.5800 to €15.7800 [3]. - On November 11, 2025, the company purchased 43,575 shares, with average prices between €15.5482 and €15.6214 [3]. - On November 12, 2025, a total of 69,000 shares were acquired, with average prices from €14.1826 to €14.2775 [3]. - On November 13, 2025, Pluxee bought 54,000 shares, with average prices ranging from €14.4347 to €14.5059 [3]. - On November 14, 2025, the company completed transactions for 57,000 shares, with average prices between €13.8690 and €13.8803 [3]. Company Overview - Pluxee operates in 28 countries, focusing on Employee Benefits and Engagement, providing solutions in Meal & Food, Well-being, Lifestyle, Reward & Recognition, and Public Benefits [4]. - The company has over 5,600 engaged team members and serves more than 500,000 clients, impacting over 37 million consumers and 1.7 million merchants [4]. - With over 45 years of experience, Pluxee aims to create a positive impact on local communities and promote employee well-being [4].

Core Insights - Pluxee maintains a positive outlook for Fiscal 2026 following regulatory reforms in Brazil that will impact its financials starting mid-year Fiscal 2026 [1][3] - The company is adopting a worst-case scenario for the implementation of the reforms, which include a cap on merchant commission rates, reduced reimbursement delays, and interoperability of meal benefits [2][3] - Pluxee anticipates a return to sustainable, profitable growth from the second half of Fiscal 2027 onwards, contingent on the full confirmation of the announced measures [3] Financial Expectations - Total revenues are expected to remain stable like-for-like in Fiscal 2026, contrasting with previously announced high-single digit organic growth [8] - A slight organic expansion in Recurring EBITDA margin is anticipated in Fiscal 2026, compared to a previous increase of +100 basis points [8] - The average Recurring cash conversion rate is projected to be around 80% over Fiscal 2024-2026 [8] Legal Considerations - The company is considering legal action against the implementation of the new measures, in collaboration with the Brazilian professional association ABBT [4] Company Overview - Pluxee operates in 28 countries, providing a range of employee benefits and engagement solutions, with a focus on meal and food, well-being, lifestyle, and public benefits [5] - The company has over 5,600 team members and serves more than 500,000 clients, 37 million consumers, and 1.7 million merchants [5]